Section 3.2.S.2.3 is typically provided only in the restricted part of the DMF. Nevertheless, the open part should contain sufficient information to enable the drug product manufacturer to take full responsibility for the evaluation of the suitability of the specification for the API to control its quality for use in the manufacture of the drug product (CTD).